Arkolith/Insider Trading/KNSA/Form 4

Ragosa Mark

CHIEF FINANCIAL OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Oct 30, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 28, 2025Option exercise(M)100$30.93$3K31K
Oct 28, 2025Sell(S)100$41.00$4K31K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 28, 2025Option exercise(M)100—$020K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001835458-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML